Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 7/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
| ▸ | SYK | P43405 | 7/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.42 |
| ▸ | MAPK3 | P27361 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 10/20 | 0.42 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.41 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12113532 | 0.87 | IRAK4 (0.52) | AURKBKDRIRAK4MAP3K7 | |
| SCHEMBL12113964 | 0.83 | SYK (0.47) | AURKBKDRSYKIRAK4 | |
| SCHEMBL10171970 | 0.81 | IRAK4 (0.57) | AURKBKDRSYKKCNH2MAPK3 | |
| SCHEMBL12113706 | 0.80 | SYK (0.47) | AURKBKDRSYKIRAK4 | |
| SCHEMBL12113709 | 0.80 | SYK (0.45) | AURKBKDRSYKIRAK4MAP3K7 | |
| SCHEMBL13660396 | 0.78 | SYK (0.36) | AURKBSYKKCNH2MAPK3MAPK1 | |
| SCHEMBL12113544 | 0.76 | IRAK4 (0.48) | IRAK4MAP3K7 | |
| SCHEMBL12113698 | 0.75 | IRAK4 (0.49) | IRAK4MAP3K7 | |
| SCHEMBL1306299 | 0.75 | AURKB (0.40) | AURKBKDRSYKKCNH2MAPK3 | |
| SCHEMBL12113966 | 0.73 | IRAK4 (0.46) | AURKBKDRSYKIRAK4MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053434-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, JAK2 | AURKB 265/4885KDR 560/4885SYK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.